They also highlight that IDH mutation is a target for small molecule inhibition and immune therapy in diffuse astrocytomas and oligodendrogliomas, while the BRAF pathway is targetable in circumscribed gliomas [10]. Here, IDH2 is linked to central nervous system cancer.